Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:東京医科大学3施設で行った滲出性加齢黄斑変性(AMD)に対するラニビズマブ療法の結果の報告。対象と方法:治療歴のないAMD 103例104眼を対象とした。男性78眼,女性26眼で,年齢は51~96歳(平均75歳)である。脈絡膜新生血管(CNV)の型と治療前視力に基づいて治療方法と再投与の基準を決めてラニビズマブ硝子体注射を行い,6か月以上の成績を検討した。視力はlogMARで評価し,0.3以上の変化を改善または悪化とした。結果:平均視力は3か月後と6か月後に有意に改善した(それぞれp<0.01)。6か月後の視力は20%で改善し,90%で維持された。CNVの型別では,classic AMDとポリープ状脈絡膜血管症で3か月後と6か月後の視力は有意に改善した。結論:統一基準にしたがって行われたラニビズマブ硝子体注射で,3か月後と6か月後の視力が維持または改善した。
Abstract. Purpose:To report the outcome of intravitreal ranibizumab for exudative age-related macular degeneration(AMD)by 3 hospitals of Tokyo Medical University. Cases:This prospective study was made on 104 eyes of 103 cases. The series comprised 78 male and 26 female eyes. The age ranged from 51 to 96 years,average 75 years. Treatment was performed in accordance to a protocol regarding type of CNV and initial visual acuity. Cases were followed up for 6 months. Visual acuity was evaluated as logMAR. Change by 0.3 or more was regarded as significant. Results:Averaged visual acuity improved significantly 3 and 6 months after treatment(each:p<0.01). Visual acuity improved in 20% and remained the same in 90%. Visual acuity after 3 and 6 months improved significantly in eyes with classic AMD and polypoid choroidal vasculopathy. Conclusion:Visual acuity improved or was maintained 3 and 6 months after intravitreal ranibizumab performed in accordance to a unified protocol.
Copyright © 2011, Igaku-Shoin Ltd. All rights reserved.